179 related articles for article (PubMed ID: 38287133)
1. Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia.
Dam M; Centanni M; Friberg LE; Centanni D; Karlsson MO; Stensig Lynggaard L; Johannsdottir IM; Wik HS; Malmros J; Vaitkeviciene GE; Griskevicius L; Hallböök H; Jónsson ÓG; Overgaard U; Schmiegelow K; Hansen SN; Heyman M; Albertsen BK
Leukemia; 2024 Apr; 38(4):712-719. PubMed ID: 38287133
[TBL] [Abstract][Full Text] [Related]
2. Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study.
Lynggaard LS; Rank CU; Hansen SN; Gottschalk Højfeldt S; Henriksen LT; Jarvis KB; Ranta S; Niinimäki R; Harila-Saari A; Wolthers BO; Frandsen TL; Heyman M; Schmiegelow K; Albertsen BK
Blood Adv; 2022 Jan; 6(1):138-147. PubMed ID: 34625787
[TBL] [Abstract][Full Text] [Related]
3. Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia.
Lynggaard LS; Vaitkeviciene G; Langenskiöld C; Lehmann AK; Lähteenmäki PM; Lepik K; El Hariry I; Schmiegelow K; Albertsen BK
Br J Haematol; 2022 Jun; 197(6):745-754. PubMed ID: 35344210
[TBL] [Abstract][Full Text] [Related]
4. Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.
Mesegué M; Alonso-Saladrigues A; Pérez-Jaume S; Comes-Escoda A; Dapena JL; Faura A; Conde N; Català A; Ruiz-Llobet A; Zapico-Muñiz E; Camós M; Rives S
Hematol Oncol; 2021 Dec; 39(5):687-696. PubMed ID: 34397119
[TBL] [Abstract][Full Text] [Related]
5. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
[TBL] [Abstract][Full Text] [Related]
6. Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group.
Brigitha LJ; Fiocco M; Pieters R; Albertsen BK; Escherich G; Lopez-Lopez E; Mondelaers V; Vora A; Vrooman L; Schmiegelow K; van der Sluis IM;
Eur J Cancer; 2022 Feb; 162():65-75. PubMed ID: 34954438
[TBL] [Abstract][Full Text] [Related]
7. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.
Tong WH; Pieters R; Kaspers GJ; te Loo DM; Bierings MB; van den Bos C; Kollen WJ; Hop WC; Lanvers-Kaminsky C; Relling MV; Tissing WJ; van der Sluis IM
Blood; 2014 Mar; 123(13):2026-33. PubMed ID: 24449211
[TBL] [Abstract][Full Text] [Related]
8. Clinical application of asparaginase activity levels following treatment with pegaspargase.
Bleyer A; Asselin BL; Koontz SE; Hunger SP
Pediatr Blood Cancer; 2015 Jun; 62(6):1102-5. PubMed ID: 25393506
[TBL] [Abstract][Full Text] [Related]
9. How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.
Burke MJ
Future Oncol; 2014 Dec; 10(16):2615-27. PubMed ID: 24983955
[TBL] [Abstract][Full Text] [Related]
10. Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06.
Albertsen BK; Harila-Saari A; Jahnukainen K; Lähteenmäki P; Riikonen P; Möttönen M; Lausen B
Leuk Lymphoma; 2019 Jun; 60(6):1469-1475. PubMed ID: 30632847
[TBL] [Abstract][Full Text] [Related]
11. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
12. Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia.
Gottschalk Højfeldt S; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Marquart HV; Vaitkeviciene G; Lepik K; Heyman M; Schmiegelow K; Albertsen BK
Blood; 2021 Apr; 137(17):2373-2382. PubMed ID: 33150360
[TBL] [Abstract][Full Text] [Related]
13. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.
Tram Henriksen L; Gottschalk Højfeldt S; Schmiegelow K; Frandsen TL; Skov Wehner P; Schrøder H; Klug Albertsen B;
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28660740
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEG-l-asparaginase product.
Matteo C; Colombini A; Bettini LR; Porcu L; Barzaghi S; Ceruti T; Silvestri D; Amoroso A; Dell'Acqua F; Gotti G; Nastasi C; Zucchetti M; Rizzari C
Pediatr Blood Cancer; 2022 Sep; 69(9):e29753. PubMed ID: 35561075
[TBL] [Abstract][Full Text] [Related]
15. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.
Ettinger LJ; Kurtzberg J; Voûte PA; Jürgens H; Halpern SL
Cancer; 1995 Mar; 75(5):1176-81. PubMed ID: 7850718
[TBL] [Abstract][Full Text] [Related]
16. Clinical Characteristics of Intravenous PEG-Asparaginase Hypersensitivity Reactions in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia [Formula: see text].
Browne EK; Moore C; Sykes A; Lu Z; Jeha S; Mandrell BN
J Pediatr Oncol Nurs; 2018; 35(2):103-109. PubMed ID: 29161979
[TBL] [Abstract][Full Text] [Related]
17. Allergic-like reactions to asparaginase: Atypical allergies without asparaginase inactivation.
Kloos RQ; Pieters R; Escherich G; van der Sluis IM
Pediatr Blood Cancer; 2016 Nov; 63(11):1928-34. PubMed ID: 27376478
[TBL] [Abstract][Full Text] [Related]
18. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences.
Burke MJ; Zalewska-Szewczyk B
Future Oncol; 2022 Mar; 18(10):1285-1299. PubMed ID: 35107320
[TBL] [Abstract][Full Text] [Related]
19. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.
Salzer W; Bostrom B; Messinger Y; Perissinotti AJ; Marini B
Leuk Lymphoma; 2018 Aug; 59(8):1797-1806. PubMed ID: 29045165
[TBL] [Abstract][Full Text] [Related]
20. Retrospective cohort study monitoring PEG-asparaginase activity in acute lymphoblastic leukemia patients with and without premedication.
Losasso M; Bostrom B; Messinger Y
F1000Res; 2019; 8():1007. PubMed ID: 32089823
[No Abstract] [Full Text] [Related]
[Next] [New Search]